Group 1 - The company is developing a small molecule peptide drug for obesity and diabetes, currently in the preclinical stage with promising preliminary data and plans for clinical transition [2] - The drug's mechanism and target differ from GLP-1 drugs like Semaglutide, showing significant weight loss efficiency in diabetic obese mouse studies compared to Semaglutide [2] - The drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves various metabolic indicators [2] Group 2 - The company will fulfill its information disclosure obligations regarding any external collaborations based on progress, with specific announcements to follow [2]

Core Viewpoint - The company is advancing its small molecule peptide drug for obesity and diabetes, currently in the preclinical stage, with promising early data and plans for clinical translation [1] Group 1: Drug Development - The small molecule peptide drug targets different mechanisms compared to GLP-1 drugs like semaglutide [1] - Preclinical data indicates the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves various metabolic indicators [1] - In studies involving diabetic obese mice, the drug demonstrated significantly better weight loss efficiency compared to semaglutide [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 1.018 billion yuan, a year-on-year decrease of 5.28% [1] - The net profit attributable to shareholders was 446.78 million yuan, reflecting a substantial year-on-year decline of 90.22% [1]

每经AI快讯，11月10日，万邦德（002082）在互动平台表示，公司在研的小分子多肽新药，目前在肥 胖、糖尿病等适应症领域处于临床前阶段，已取得良好的前期数据，有计划推进临床转化。其与司美格 鲁肽等GLP-1类药物相比，靶点与作用机制不同。临床前数据显示，其既减肥、燃脂又减少肌肉流失， 还能降糖、抗炎，同时改善多项代谢指标，尤其在糖尿病肥胖小鼠研究中，降低体重效率显著优于司美 格鲁肽。 ...

人民财讯11月10日电，万邦德（002082）11月10日在互动平台表示，公司在研的小分子多肽新药，目前 在肥胖、糖尿病等适应症领域处于临床前阶段，已取得良好的前期数据，有计划推进临床转化。其与司 美格鲁肽等GLP-1类药物相比，靶点与作用机制不同。临床前数据显示，其既减肥、燃脂又减少肌肉流 失，还能降糖、抗炎，同时改善多项代谢指标，尤其在糖尿病肥胖小鼠研究中，降低体重效率显著优于 司美格鲁肽。 ...

Core Viewpoint - The company Wanbangde is developing a small molecule peptide drug targeting obesity and diabetes, currently in the preclinical stage with promising early data, and plans to advance to clinical trials [2] Group 1: Drug Development - The small molecule peptide drug is in the preclinical stage for indications such as obesity and diabetes [2] - Early data shows significant efficacy in weight loss, fat burning, and muscle preservation, along with glucose reduction and anti-inflammatory effects [2] - The drug demonstrates superior weight loss efficiency compared to Semaglutide in studies involving diabetic obese mice [2] Group 2: Mechanism of Action - The drug has a different target and mechanism of action compared to GLP-1 class drugs like Semaglutide [2] - It aims to improve multiple metabolic indicators, indicating a broader therapeutic potential [2]

Core Viewpoint - The company is advancing a small molecule peptide drug targeting obesity and diabetes, currently in the preclinical stage, with promising preliminary data and plans for clinical translation [1] Group 1: Drug Development - The small molecule peptide drug shows different targets and mechanisms of action compared to GLP-1 drugs like Semaglutide [1] - Preclinical data indicates the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, and has anti-inflammatory effects [1] - The drug significantly improves multiple metabolic indicators, particularly demonstrating superior weight loss efficiency in studies involving diabetic obese mice compared to Semaglutide [1]